Join the Oncology Voice Network. Join for Free
Quantitative Clinical Pharmacology of T‐Cell Engaging Bispecifics: Current Perspectives and Opportunities
quantitative clinical pharmacology T-Cell TDB bispecificss

Quantitative Clinical Pharmacology of T‐Cell Engaging Bispecifics: Current Perspectives and Opportunities


Share This Article


Summary

  • The pharmacological response of TDBs involves complex interactions between T-cells, tumor cells, and TDBs, posing challenges in understanding pharmacokinetics, tissue distribution, target engagement, and exposure-response relationships.
  • Dosing strategy is crucial for determining the therapeutic window, aiming to maximize efficacy while managing mechanism-related adverse events like cytokine release syndrome and neurological issues, which are most prominent during initial treatment cycles.
  • Kinetic characterization of exposure/target engagement and safety/efficacy outcomes is essential for designing optimal dosing regimens to balance the benefit/risk of TDB agents.
  • The review covers clinical pharmacological considerations in TDB drug discovery and development, summarizes current clinical developments, and suggests future opportunities for insights through quantitative clinical pharmacology.

Advancements in antibody engineering and recent clinical successes have led to enthusiasm for the development of bispecific modalities with the unique ability to bind to two distinct antigens or two different epitopes on the same antigen. T‐cell directing/engaging bispecific agents (TDBs), in particular, are rapidly becoming an important class of molecules in oncology drug development. These agents enhance recruitment of effector cells (e.g., cytotoxic T‐cells) to tumor‐associated/specific antigens for targeted cell killing. Like other T‐cell engaging therapies, TDBs engage the host’s T‐cells thereby driving deep and durable clinical response beyond treatment termination. However, unlike chimeric antigen receptor T‐cell therapies, which take weeks from collection of patients’ T‐cells to availability of treatment product, TDBs are available off‐the‐shelf.

Click for Source Download PDF version
quantitative clinical pharmacology, T-Cell, TDB, bispecificss

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Reengineering CAR T for Solid Tumors: What Glioblastoma Has Taught Us with Christine Brown, Ph.D.
Partner Avatar Monty Pal

Reengineering CAR T for Solid Tumors: What Glioblastoma Has Taught Us with Christine Brown, Ph.D.

Article
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
OVN Avatar Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Article
Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals
OVN Avatar R. Kurzrock, L.A. Gurski, R.W. Carlson, D.S. Ettinger, S.M. Horwitz, S.K. Kumar, L. Million, M. von Mehren, A.B. Benson III

Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals

Article
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
OVN Avatar Barbara Kiesewetter , Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Ma

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies

Article
The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions
OVN Avatar Charles L. Bennett , Sumimasa Nagai , Andrew C. Bennett , Shamia Hoque , Chadi Nabhan , Martin W. Schoen , William J. Hrushesky , Stefano Luminari , Paul Ray , Paul R. Yarnold , Bart Witherspoon , Josh Riente , Laura Bobolts , John Brusk , Rebecca Tombles

The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions

Article
Large pharma companies reduced headcounts by more than 22K in 2025 as $300B patent cliff looms
OVN Avatar Angus Liu

Large pharma companies reduced headcounts by more than 22K in 2025 as $300B patent cliff looms

Explore OVN